Author:
Maaske Jill,Sproule Stephanie,Falsey Ann R.,Sobieszczyk Magdalena E.,Luetkemeyer Anne F.,Paulsen Grant C.,Riddler Sharon A.,Robb Merlin L.,Rolle Charlotte-Paige,Sha Beverly E.,Tong Tina,Ahani Bahar,Aksyuk Anastasia A.,Bansal Himanshu,Egan Timothy,Jepson Brett,Padilla Marcelino,Patel Nirmeshkumar,Shoemaker Kathryn,Stanley Ann Marie,Swanson Phillip A.,Wilkins Deidre,Villafana Tonya,Green Justin A.,Kelly Elizabeth J.
Abstract
BackgroundBreakthrough severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in coronavirus disease 2019 (COVID-19) vaccinees typically produces milder disease than infection in unvaccinated individuals.MethodsTo explore disease attenuation, we examined COVID-19 symptom burden and immuno-virologic responses to symptomatic SARS-CoV-2 infection in participants (AZD1222: n=177/17,617; placebo: n=203/8,528) from a 2:1 randomized, placebo-controlled, phase 3 study of two-dose primary series AZD1222 (ChAdOx1 nCoV-19) vaccination (NCT04516746).ResultsWe observed that AZD1222 vaccinees had an overall lower incidence and shorter duration of COVID-19 symptoms compared with placebo recipients, as well as lower SARS-CoV-2 viral loads and a shorter median duration of viral shedding in saliva. Vaccinees demonstrated a robust antibody recall response versus placebo recipients with low-to-moderate inverse correlations with virologic endpoints. Vaccinees also demonstrated an enriched polyfunctional spike-specific Th-1-biased CD4+ and CD8+ T-cell response that was associated with strong inverse correlations with virologic endpoints.ConclusionRobust immune responses following AZD1222 vaccination attenuate COVID-19 disease severity and restrict SARS-CoV-2 transmission potential by reducing viral loads and the duration of viral shedding in saliva. Collectively, these analyses underscore the essential role of vaccination in mitigating the COVID-19 pandemic.
Subject
Immunology,Immunology and Allergy
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献